title: Does a cost-effective approach for the determination of KRAS mutations maximize the patient's benefit in a clinical setting?
authors: Takashi
authors: T
authors: Kobunai
authors: Toshiaki
authors: T
authors: Watanabe
authors: Yoko
authors: Y
authors: Yamamoto
authors: Toshio
authors: T
authors: Fukusato
mesh_terms: D003110:Colonic Neoplasms / Q000235:genetics; D003362:Cost-Benefit Analysis; D004252:DNA Mutational Analysis / Q000191:economics* / Q000379:methods*; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics*; D016133:Polymerase Chain Reaction / Q000191:economics* / Q000379:methods*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics*
chemical_list: C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins